Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10724102B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 26, 2016 |
| Grant date | Jul 28, 2020 |
| Priority date | — |
| Expiry date | Oct 26, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.